53 results
8-K
AMPE
Ampio Pharmaceuticals Inc
28 Apr 22
Conference Call Script
8:00am
relating to the COVID-19 pandemic, and the risk that the data is not accepted by the FDA; our ability to navigate the regulatory approval process … and the unpredictable nature of the ongoing COVID-19 pandemic; adverse developments in our research and development activities; potential liability if any
8-K
EX-99.1
AMPE
Ampio Pharmaceuticals Inc
28 Apr 22
Conference Call Script
8:00am
these confounding facts, but we believe that the Per Protocol analysis suggests that, but for the confounding pandemic, it could have been
8-K
EX-99.1
6pn qn1pyotad
20 Apr 22
Ampio Provides Regulatory Update
9:43pm
8-K
EX-99.1
cqah22efdfsh sp
29 Mar 22
Ampio Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Operational Highlights
4:17pm
8-K
EX-99.1
lg48 dicyb
2 Mar 22
Complete analysis of AP-013 data show Ampion reduced pain with statistical significance
4:38pm
8-K
EX-99.1
smpma 4f1e0vdgog75d
16 Dec 21
Regulation FD Disclosure
4:01pm
424B5
wj4o7ofp2 kkvl
14 Dec 21
Prospectus supplement for primary offering
5:06pm
8-K
EX-99.1
yfcbltosq9f w1x4zfy
15 Sep 21
Other Events
9:25am
8-K
EX-99.1
hk1cs26
5 May 21
Results of Operations and Financial Condition
4:05pm
8-K
EX-99.1
5cncncxzfvs
3 Mar 21
Ampio Pharmaceuticals, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update
4:05pm
8-K
EX-99.1
a4gqko iz5p6
29 Dec 20
Other Events
4:17pm